drugset / Trial / NCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Timeline
- Start
- 2021-05-13
- Primary completion
- 2022-07-08
- Completion
- 2022-10-27
Publications
- Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025 Aug;13(8):674-684. doi: 10.1016/S2213-8587(25)00092-0. Epub 2025 Jun 30.
- Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 0.5 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 4 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 8 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 12 mg | Subcutaneous |